Donor Deaths in India Highlight Surrogacy Perils
By Swapna Majundar,
Thomson Reuters Foundation
| 06. 16. 2014
Untitled Document
When Yuma Sherpa told doctors at a private fertility clinic here that she wanted to back out, her husband's lawyer says they encouraged her to keep going.
Sherpa was assured the pain of the injections to make her super-ovulate, or produce far more than the usual one egg during her menstrual cycle, would end once her eggs were harvested. But when the 26-year-old shop assistant died after the surgery in January, her husband filed a complaint with the Delhi Medical Council charging medical negligence.
"The tragic death of the young woman in the prime of her life is shocking," Sudha Sundararaman, vice president of the All India Democratic Women's Association, told Women's eNews in a phone interview. "While there are laws in the country to prevent the sale of blood, there are no binding guidelines for such procedures related to assisted reproductive technology. With no monitoring of their impact on the health of women, most clinics just do as they please."
Sundararaman's Delhi-based association is one of several women's groups seeking a criminal investigation into Sherpa's case and...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...